Program
SAR446268
A development code.
In Sanofi's pipeline, DMPK AAV gene therapy
. Its studies are mostly in Myotonic Dystrophy, led by Sanofi.
Furthest: phase 2, since Feb 19, 20251 company-led study, 1 open or runningNext primary completion: Feb 28, 2029 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 11 open or running | phase 2since Feb 19, 2025 | Feb 19, 2025 | Feb 28, 2029phase 2 · NCT06844214 |
- Named in Sanofi’s own pipeline as
SAR446268
, phase 1, as of Sep 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 19, 2025First study: phase 2 study in Myotonic DystrophyFirst studyNCT06844214 · 32 planned · United States, Argentina, Australia and more
Ahead
- Feb 28, 2029Primary completion: phase 2 study in Myotonic DystrophyNCT06844214
TargetBeta
“DMPK AAV gene therapy”the company's pipeline, read by Claude · source
“The purpose of this study is to evaluate the safety and efficacy of SAR446268 in knocking down dystrophia myotonica protein kinase (DMPK) messenger ribonucleic acid (mRNA) levels and improving neuromuscular function in DM1 participants receiving a single intravenous (IV) administration of SAR446268.”study text, read by Claude · the study
Other programs on DMPK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| AOC 1001 | Novartis | phase 3 | 4 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06844214Myotonic Dystrophy · United States, Argentina, Australia and more | 2 | Recruiting | Feb 28, 2029 | 32 |
How it is read
Names in the registry
- “SAR446268”, 1 entry
Codes read as this program: SAR446268.
Conditions, from the studies’ own filings
- Myotonic Dystrophy, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.